Core Viewpoint - X4 Pharmaceuticals has successfully closed a public offering of 52,844,000 shares, raising approximately $155.3 million to support its operations and development of therapies for rare hematology diseases [1][2]. Group 1: Offering Details - The public offering price was set at $2.90 per share, with an additional option for underwriters to purchase up to 6,984,000 shares [1]. - Pre-funded warrants were also offered at a price of $2.899, allowing the purchase of up to 700,000 shares at an exercise price of $0.001 per share [1]. - After the offering, the total shares outstanding increased to 79,214,708 [1]. Group 2: Underwriters and Registration - Leerink Partners, Stifel, and Guggenheim Securities served as joint bookrunning managers for the offering [2]. - A shelf registration statement for these securities was filed with the SEC on August 14, 2023, and became effective on August 24, 2023 [3]. Group 3: Company Overview - X4 Pharmaceuticals focuses on developing innovative therapies for patients with rare hematology diseases, particularly through its CXCR4 antagonist, mavorixafor [5]. - The company is currently marketing mavorixafor in the U.S. under the brand name XOLREMDI® and is conducting a pivotal Phase 3 clinical trial for chronic neutropenic disorders [5].

Core Viewpoint - X4 Pharmaceuticals has announced a public offering of 45,860,000 shares of common stock priced at $2.90 per share, aiming to raise approximately $135 million to fund the development of its drug mavorixafor and for general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes pre-funded warrants for up to 700,000 shares at a price of $2.899 each, with an exercise price of $0.001 per share [1]. - The offering is expected to close on October 27, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 6,984,000 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the pivotal Phase 3 development of mavorixafor for chronic neutropenic disorders, along with general administrative expenses, capital expenditures, and working capital [2]. Group 3: Company Background - X4 Pharmaceuticals focuses on developing therapies for rare hematology diseases, with mavorixafor being an orally available CXCR4 antagonist currently marketed in the U.S. as XOLREMDI® [5]. - The company is conducting a global Phase 3 clinical trial (4WARD) for mavorixafor in patients with chronic neutropenic disorders [5].

Core Insights - X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the 30th Annual Congress of the European Hematology Association, highlighting positive results from a Phase 2 trial of mavorixafor for chronic neutropenia [1][2] - Mavorixafor is positioned as a potential first oral treatment for chronic neutropenia in over 30 years, with ongoing Phase 3 trials supporting its efficacy and safety [2][8] Company Overview - X4 Pharmaceuticals focuses on developing therapies for rare immune system diseases, with mavorixafor being a key product currently marketed in the U.S. as XOLREMDI® [9] - The company is headquartered in Boston, Massachusetts, and is actively pursuing additional indications for mavorixafor [9] Clinical Trial Details - The Phase 2 trial was a six-month open-label study involving 23 participants with various forms of chronic neutropenia, assessing the safety and efficacy of mavorixafor [3][7] - The ongoing pivotal Phase 3 trial, named 4WARD, aims to evaluate mavorixafor's efficacy and safety in a larger cohort of 150 participants with chronic neutropenia [8] Research Findings - The Phase 2 study demonstrated meaningful increases in functional neutrophils, with many participants able to reduce their G-CSF dosing when treated with mavorixafor [1][6] - Mavorixafor acts as a CXCR4 antagonist, mobilizing neutrophils from the bone marrow into the bloodstream, which is crucial for managing chronic neutropenia [5][6]